Novo's investigational CagriSema, a GLP-1 and amylin analog, demonstrated ~21% average weight loss with lower doses in the REDEFINE 9 trial, presented at ObesityWeek® 2026 and published in The Lancet Diabetes &…

详细摘要

REDEFINE 9 trial showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with…

PLAINSBORO, N.J. and BAGSVÆRD, Denmark, Nov. 14, 2026 /PRNewswire/ -- Today, Novo Nordisk announced primary results from the phase 3 REDEFINE 9 trial of investigational CagriSema, a fixed-dose combination of the long-acting amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide, in adults with overweight or obesity. REDEFINE 9 is the first phase 3 trial for weight management to evaluate CagriSema at doses lower than the maximum dose that has been evaluated in the REDEFINE clinical program, 2.4 mg / 2.4 mg.1 The results were presented at ObesityWeek® 2026 in Washington, DC, US, and simultaneously published in The Lancet Diabetes & Endocrinology.1,2

"Understanding how people respond to treatment across different doses is an important part of obesity research," said Martin Holst Lange, executive vice president, chief scientific officer and head of Research & Development at Novo. "REDEFINE 9 studied each dose against its own placebo comparison over 68 weeks. The results add to our understanding of CagriSema across doses and, together with the broader REDEFINE program, inform how we continue to develop the combination of cagrilintide and semaglutide. We look forward to sharing these data with the scientific community at ObesityWeek®."

In REDEFINE 9, both doses of CagriSema produced significantly greater estimated average weight loss than placebo at week 68: 20.7% and 21.0%, respectively, compared with 2.0% with placebo (estimated treatment difference −18.8 and −19.0 percentage points; p

Based on the treatment regimen estimand,† estimated average weight loss at week 68 was 19.4% and 18.6% with CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg, respectively, compared with 4.6% with placebo (estimated treatment difference −14.7 and −13.9 percentage points; p

Change in body weight with CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg at week 68 in REDEFINE 9 (efficacy estimand*)1

The trial was not powered to detect differences between the two CagriSema doses.

Change in…

The…

文章开头，摘自PR Newswire。如需阅读全文，请前往媒体网站。